{"groups":[{"description":"Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.\n\nindium In 111 anti-CD45 monoclonal antibody BC8: Given IV\n\nyttrium Y 90 anti-CD45 monoclonal antibody BC8: Given IV\n\nperipheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell transplant","id":"FG000","title":"Treatment (Yttrium-90 Anti-CD45 Monoclonal Antibody BC8)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}